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Abstract 
Background 
Human papillomavirus (HPV) are the most commonly known sexually transmitted 
agents. To date, few reports are available on distribution of most prevalent and 
variants types of HPV in Arab women. Therefore, the aim of this study was to 
determine the age specific distribution of HPV types among Arab women being 
subjected to routine Pap smear test in State of Qatar. 
Methods 
Total 3008 pap smears have been collected in ThinPrep vials from the Arab women 
seeking routine gynecological care visiting Women's Hospital, Hamad Medical 
Corporation (HMC) in Qatar. Viral DNA from ThinPrep samples was extracted and 
was screened for HPV DNA by real-time PCR using Ll HPV specific (GP5+/6+) 
primers. The types specific distribution of the viruses was determined by HPV high 
and low risk typing RT-PCR kits and PCR-based sequencing (Genewiz, Inc, USA). 
Results 
Based on the collected data, HPV DNA was detected in 182 women (6%), and 17 
different HPV genotypes were detected, comprising high-risk, intermediate and low-
risk genotypes. The prevalence of HPV infection was seen in 6.2% Qatari and 5.9% 
non-Qatari women. With regard to age, 5.1% HPV infection were found in women 
16-24 years of age, 5.8% in women 25-34 years of age, 5.5% in women 35-44 years 
of age, 6.5% in women 45-54 years and 7.2% in women more than 55 years old. 
Conclusion 
At the end, our study showed a relatively low prevalence (6%) of HPV infection and 
presence of a varied genotypic profile of HPV with a high prevalence of low risk 
HPV genotype 81 among the Arab women residing in State of Qatar when compared 
to the Middle Eastern and North African (MENA) countries . 
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Chapter !-Introduction 
Human Papillomavirus (HPV) is the most common sexually transmitted infection and 
major causal agent for cervical cancer [Walboomers et al., 1999]. Worldwide, cervical 
cancer is the fourth most common cancer among women, with an estimated 83,195 
new cases and 35,673 deaths in 2012 [Ferlay et al., 2013]. More than 85% of these 
cases and deaths occur in developing countries [Jemal et al., 2011]. Currently, more 
than 200 HPV genotypes have been identified and characterized based on nucleotide 
sequence relatedness in L1 gene, which codes for the major HPV capsid protein 
[Clifford, Smith, Plummer, Munoz, & Franceschi, 2003]. Among these, based on their 
oncogenic potential via associations with cervical cancer and precancerous lesions, 
about 30 to 40 genotypes are divided into high-risk {HR), causing cervical neoplasia 
and low-risk (LR) HPV genotypes, which causes benign signs and symptoms 
[Clifford et al., 2003]. Furthermore, these genomic variants can be considered as 
markers of specific HPV genomes and accordingly can be used in epidemiological 
and etiological studies in order to investigate the transformation of HPV within and 
among populations. 
The prevalence of HPV infections in women within the general population 
differs considerably between countries and regions, as well as within regions, ranging 
from 1.6-41.9% [Seoud, 2012].1n Extended Middle Eastern and North African 
(EMENA) countries, HPV prevalence reported between 0% and 25% in women with 
normal cytology and up to 98% in women with abnormal cytology [Khan, 2009; 
Seoud, 2012].Very limited data is available on the prevalence ofHPV infection in the 
Arab countries where social, cultural and sexual behaviors differ greatly from the 
more-well reported Western countries [Wellings et al., 2006]. 
Presently, two FDA approved HPV vaccines (Gardasil and Cervarix) have 
been used to reduce the incidence of cervical cancer associated with HPV infections. 
These vaccines have been prepared from DNA free viral particles combined with an 
adjuvant by recombinant technology. Gardasil is a quadrivalent (types 6, 11, 16 and 
18) HPV vaccine that prevents around 100% of precancerous lesions associated with 
HPV 16 and HPV 18. While, Cervarix is a bivalent (types 16 and 18) vaccine [Cutt et 
al., 2007]. 
1 
0 
• 
• 
Moreover, it bas been revealed that the distribution of different HPV 
genotypes varies from one region to another, which influences the effectiveness of the 
HPV vaccines. In addition, the lack of studies on HPV prevalence and HPV genotype 
distribution affect the designing of effective vaccine used in different population [Al-
Thani et al., 2010]. The data of HPV prevalence and genotypes distribution among 
Arab women is limited. Therefore, in the present study, we aimed to determine the 
HPV prevalence and distribution ofHPV genotypes among Arab women residing in 
State of Qatar with normal and abnormal cytology. 
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Chapter 2-Literature of review 
HPVGenome: 
Human papillomaviruses (HPV) are group of small, non-enveloped circular double-
stranded DNA viruses within an icosahedral capsid that infect the human epithelium . 
There are more than 200 different genotypes of HPV have been identified. Among 
these, about 30 to 40 infect human genital tract and divided into high-risk. 
(HR)genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, and 58) and low risk 
(LR)genotypes {6, 11, 40, 42, 43, 44, 54, 81 and 90) [Munoz et al., 2003]. Among the 
high-risk (HR) genotypes, HPV 16 is the most common oncogenic type that is 
responsible for almost half of all cervical cancers, and HPV 16 and 18 together are 
responsible for almost 70% of cervical cancers [Clifford et al., 2003].Among the low-
risk (LR) genotypes, HPV 6 and 11 are the most common types associated with 
genital warts and responsible for almost 90% of these lesions. 
HPV genome is circular and approximately 8000 bp, which encode eight major 
proteins, 6 located in the "early" region and 2 in the "late" region. The "early" proteins 
(E6, E7, El, E2, E4, and E5) have regulatory function. They play roles in HPV 
genome replication, transcription, cell cycle, and structural modification of infected 
cell, immune alteration and apoptosis control [Doorbar et al., 1997] While Ll and L2, 
are late proteins that encode the viral capsid protein, which is required for virus 
transmission, and survival in the environment [Graham, 2010]. 
Establishment and virulence of HPV infection 
Establishment of papillomaviruses infection requires that virus particles to get the 
access to the basal layer of epithelial cells [Doorbar, 2006]. Once they are accessed 
the basal layer of the epithelial cells, the viral genome stabilized as episome (without 
integration into the genome of the host cell). Expression of viral replication proteins, 
El and E2 is required in this phase ofHPV infection. The E2 protein is required for 
initiation of viral DNA replication. Also, E2 protein is a DNA protein that is required 
for recruitment ofthe El helicase to the viral origin, which binds to cellular proteins 
necessary for DNA replication [Dell et al., 2003]. It is also considered as transcription 
factor that regulates the expression of the viral early proteins "oncogenes" (E6 and 
E7).Lesions in the cervix caused by HPV, is related to the expression of the viral 
oncogenes (E6 and E7) that lead to increase proliferation of basal epithelial cells 
[Doorbar, 2006]. The activity of these genes (E6 and E7) during natural infection, 
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allows the small number of infected cells to expand that subsequently produce 
infectious virions [Madison, 2003]. The mechanism by which papillomaviruses 
stimulate the progression of cell cycle is well known and it is the same way that other 
tumor viruses decontrol cell growth. E7 disrupts the association between pRb and the 
E2F family of transcription factors by associating with Rb (retinoblastoma protein). 
As a result, E2F activates cellular proteins such as cyclins A and E that are required 
for viral DNA replication. E7 is also associated with other proteins required for cell 
proliferation such as histone deacetylases [Brelun et al., 1999], and cyclin-dependent 
kinase inhibitors p21 and p27 [Funk et al., 1997]. In the high-risk HPV types, the two 
proteins (E6 and E7) are expressed together from a single polycistronic mRNA 
[Stacey et al., 2000]. The main role ofE6 is its association with p53 that results in p53 
ubiquitination and degradation. This mechanism prevents apoptosis or growth arrest 
that mediates the cell cycle entry in the upper epithelial layers by E7. E6 is an anti-
apoptotic protein that is associated with Bak [Thomas & Banks, 1998] and Bax [Li & 
Dou, 2000]. The anti-apoptotic function of E6 plays an important role in developing 
cervical cancers by allowing the accumulation of secondary mutations to go 
unchecked. In high-risk HPV types, E6 protein plays an important role in mediating 
cell proliferation independently of E7 through its C-terminal PDZ ligand domain: 
PSD-95 (a 95 kDa protein involved in signalling), Dig (the Drosophiladiscs large 
protein), and Z01 (the zonula occludens 1 protein involved in maintaining epithelial 
cell polarity) [Thomas et al., 2002]. PDZ binding to the C-tenninal domain of E6 
mediate the cell proliferation [Nguyen et al., 2003] and develop metastatic tumors by 
disrupting the adhesion of normal cell. 
High-risk HPV genotypes are associated with cervical cancer that increases the 
thickness of epithelial layers based on the grade of neoplasia and decrease their 
differentiation. Lesion formation and the maintenance of viral episomes require cell 
proliferation, so all types of papillomavirus ultimately amplify and package their 
genomes for the infectious virions to be produced. This is managed by the up-
regulation of the differentiation-dependent promoter, which is within E7 ORF (P670 
in HPV16; P742 in HPV31), in many ofHPV genotypes [Bodily & Meyers, 2005; 
Spink & Laimins, 2005]. The activation of the differentiation-dependent promoter 
leads to an increase the viral proteins (E1, E2, E4 and E5) [Bodily & Meyers, 2005; 
Spink & Laimins, 2005] required for replication. 
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TheEl, E2, E4 andES proteins play an important role in viral genome amplification 
of the virus [Fehrmann, Klumpp, & Laimins, 2003]. TheEl expressed at low level, so 
it requires the presence of E2 protein to increase its binding to the targeted binding 
site. The ES is a transmembrane protein that is located in the ER (endoplasmic 
reticulum). It delays the endosomal acidification process by its association with the 
vacuolar proton ATPase [Crusius, Rodriguez , & Alonso, 2000].This mechanism of 
ES protein affects the recycling of growth factor receptors resulting to an increase in 
(epidermal growth factor)-mediated receptor signaling and maintenance of viral 
replication [Crusius et al., 2000], while the role of E4 is not well established in viral 
genome amplification. Virus assembly "packaging into infectious particles" is the last 
stage of the papilloma virus productive cycle. After the viral genome amplification, 
capsid proteins (Ll and L2) accumulate [Florin, Sapp, Streeck, & Sapp, 2002].E2 
protein is required for the assembly of infectious virions in addition to (Ll and L2) 
capsid proteins in the upper layers of epithelium [Zhao et al., 2000].Finally, the 
release of the viral particles required effective escape from the envelope at the cell 
surface of the epithelium, which is facilitated by the E4 protein. This mechanism is 
managed by disturbing the keratin network by E4 protein [Wang et al., 2004]. 
Transmission of HPV 
HPV is thought to gain its entry to the body through micro-traumas or abrasions to the 
mucosa exposing the epithelium basal cells. So the transmission of HPV is through 
direct skin-to-skin contact or through penetrative vaginal or anal intercourse [Winer et 
al., 2003].Most studies have shown and supported sexual route is the primary route of 
the genital HPV infection documenting genital warts between partners [Hernandez et 
al., 2008].The risk ofHPV infection is related to the number of sexual partners [Ho et 
al., 1998].Using condoms decrease the risk of transmission of HPV infection among 
partners. However it is not 100% protective tools, since women having sexual contact 
with men using condoms are still at risk of acquiring HPV infection [Matt, Feltman, 
& Twiggs, 2008].Despite the fact that HPV is the cmmnon pathogen that infects 
adults, but it is also found to infect children causing various mucosal and cutaneous 
types of infections. There are different modes of transmission of HPV infection 
among children including, auto and hetero inoculation, perinatal transmission, sexual 
abuse and indirect transmission through fomites. Children abuse is considered as the 
most common mode of HPV transmission among children [Syrjanen & Puranen, 
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2000]. Also, HPV could infect wgms who have never encountered vaginal 
intercourse through horizontal transmission such as floors and seats of public toilets, 
bathing resorts, public and private swimming pools, schools and private homes of a 
family with an infected individual [Syrjanen, 2010]. 
Signs and symptoms of HPV 
HPV infection causes a lot of complications start with mild to moderate symptoms 
such as genital warts, skin warts, and recurrent respiratory papillomatosis until reach 
to the severe and difficult cause, which is the cancer and there are about 600,000 
cases of cervical cancer, vulva, vagina and oropharynx every year [Arbyn et al., 
2012].HPV could infect basal epithelial cells of the skin "hands and feet" and is 
categorized as cutaneous types of HPV while mucosal HPV types infect the inner 
lining of tissues such as mouth, throat, respiratory tract and anogenital 
epithelium[Burd, 2003]. 
Many ofHPV infections are asymptomatic, staying for a short while without showing 
any symptoms and they are self-limiting infection by which the patient immune 
system clears the HPV within approximately 1-2 years [Lalonde, 2007]. 
Sexually transmitted HPV infection could lead to one of the three possible effects 
based on the HPV type involved in the site of infection [Burd, 2003]: 
1. Anogenital warts (condyloma acuminatum): appear on or around the genitals 
and anus in men and women. HPV 6 and 11 are most common types 
associated with anogenital warts, but do not lead to cancer. These warts are 
asymptomatic and HPV may be cleared in 3 to 4 months. 
2. Latent or inactive HPV infection: obvious or clear symptoms are rarely 
produced and few people can recognize that they are infected. 
3. Active HPV infection: strongly associated with high-risk HPV types that 
cause visible changes to the infected epithelial cells leading to vaginal, vulvar, 
penile, urethral, bladder, and cervical intraepithelial neoplasia. This infection 
is strongly associated with cervical cancer. 
HPV infection can cause recurrent respiratory papillomatosis (RRP) which is a rare, 
benign disease that infect the upper aerodigestive tract with no known cure. In most of 
the RRP cases, pediatric patients do not show any symptoms immediately. Since 
larynx is the most common site of infection, hoarseness is the first symptom appeared 
[Kashima, Mounts, Leventhal, & Hruban, 1993].0ther symptoms in RRP include 
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chronic cough, dyspnea, pneumonia, recurrent upper respiratory infections, acute 
respiratory distress, dysphagia and failure to thrive [Derkay & Wiatrak, 2008]. RRP 
could be potentially life threatening benign tumor of the respiratory tract [Zacharisen 
& Conley, 2006].HPV 11 is the most common type (50%-100%) in RRP cases, 
followed by HPV 6 [Gissmann et al., 1983]. 
Diagnosis of HPV infection 
Several studies have confirmed that infection of cervix with high-risk genotypes is 
considered as a precursor step to cervical cancer. Cervical cancer is a disease that 
progress from mild cervical intraepithelial neoplasia (CINl), which is a reversible 
stage, to severe cervical intraepithelial neoplasia (CIN2 or CIN3), which is 
irreversible, and last stage of this process is invasive cervical carcinoma [Holowaty, 
Miller, Rohan, & To, 1999].HPV from clinical specimens cannot be cultured in the 
laboratory and immunological tests are not sufficient to detect HPV infection. So the 
main diagnostic tools to detect HPV infection in clinical samples are cytology and 
histology. Lately, molecular methods have been emerged to detect HPV DNA in 
clinical specimens. 
• Conventional Cytology: Papanicolaou-stained (Pap) smear is primary method 
for detection of HPV infection. It is named after the pathologist George 
Papanicolaou, who introduced the method in 1949 [Holowat et al., 1999]. It is 
considered as screening tool that detect changes, often caused by HPV, in cells 
of the transformation zone of cervix. Cervical cancer incidence and mortality 
rates has been decreased half to two-third since the introduction of Pap smear 
as screening tool [Kurman, Henson, Herbst, Noller, & Schiffman, 1994].The 
reporting system for the Pap smear that replaced the CIN system is Bethesda 
System. Bethesda System was hosted in 1988 and amended in 1991 [Border, 
1992].The CIN system was hosted in 1973 and it was based on the 
architecture of the tissue and its progression from precursor lesions to invasive 
cancer. However, Bethesda System categorized the abnormalities of 
squamous cells into: ASC (Atypical Squamous Cells), LSIL (Low-Grade 
Squamous Intraepithelial lesions), HSIL (High-Grade Squamous 
Intraepithelial lesions), and squamous cell carcinoma. 
There are some limitations using Pap smear techniques to detect abnonnalities 
in cervical samples. Samples inadequacy constitutes 8% of received 
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specimens. 20 to 30% is the false-negative rates which results from clumping, 
not spread evenly on the microscope slide, of the cells and presence of blood, 
bacteria, or yeast that prevent proper detection of abnormal cells. Cervical 
cells could be distorted if the slide exposed to the air too long before being 
fixed. Human error is considered as the main limitation to an accurate 
interpretation [Burd, 2003]. 
• Histopathology: Colposcopy and colposcopy-directed biopsy are methods to 
evaluate the cervical lesion for patients who have abnormal Pap smear results. 
Low-grade and high-grade dysplasia could be detected using colposcopy. 
Biopsy is considered as diagnostic method to detect pathologic features of 
HPV infection such as hyperplasia and degenerative vacuolization of 
cytoplasm with atypical nuclei. Another method to detect the presence ofHPV 
in cervical specimens is using monoclonal and polyclonal antibodies that are 
directed to HPV common antigen, epitope of major capsid protein that is 
expressed in different HPV types [Burd, 2003]. 
• HPV DNA detection: There are two PCR methods: type-specific PCR and 
general primer PCR to detect HPV in cervical specimens. In type-specific 
PCR, method based on variations of the sequence present in E6 and E7 genes 
ofHPV. There are fourteen type-specific PCRs for detection ofhigh-risk HPV 
genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) which 
amplify 100 bp in the E7 ORF [Walboomers et al., 1999]. In general primer 
PCR, method based on using consensus primers to amplify a broad range of 
HPV genotypes. The principle of these primers is that they target conserved 
regions of the HPV such as the L1 capsid gene. MY09/MY11 primers amplify 
specific target in L1 gene producing 450 bp size products [Bosch et al., 
1995]while GP5+/GP6+ primers amplify specific target within the region 
targeted by MY09/MY11 primers producing 150 bp size products [Hutchinson 
et al., 1994]. 
Treatment of HPV infection 
Most of HPV that induces cervical changes are transient. 90% of cervical changes 
regress within 12 to 24 months by the action of the immune system eliminating HPV 
virus [Chua & Hjerpe, 1996].Cryotherapy or laser therapy is superficial ablative 
procedures that are used to treat intraepithelial lesions. In cryotherapy procedure, 
super-cooled probe is used to freeze the abnormal tissue and its surrounding to induce 
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necrosis for the abnormal lesions. In laser therapy, a laser beam of carbon dioxide is 
applied to remove abnormal tissue. Laser therapy is as effective as cryotherapy, but it 
is more expensive. A preferred treatment for squamous lesions is loop electrosurgical 
method. An electrically charged wire to remove the transformed lesion conducts this 
method. It is less expensive compared to the laser therapy and preserves the removed 
tissue for further histological analysis. Excisional cone biopsy is an effective 
procedure to manage micro-invasive cancers less than 3 mm in size. Radical 
hysterectomy is a method to control early invasive cancers. And radiotherapy is 
methods of choice to control locally advance cancers [Burd, 2003].In addition to 
surgical procedures, different antiviral agents have been used as method to treat 
cervical lesions caused by HPV such as Cidofovir, Podophyllin and IFNs. Exposure 
of cells containing HPV to Cidofovir, inhibit cell proliferation [Andrei, Snoeck, 
Piette, Delvenne, & DeClercq, 1998]. Podophyllinin combination with vidarabine, a 
DNA polymerase inhibitor, arrests the cell growth and suppresses the expression of 
HPV. gene [Okamoto et al., 1999].IFN-a is one of the approved treatment for genital 
warts. 
Prevention 
The main approaches for prevention against HPV infection is development of HPV 
vaccines. To date, two HPV vaccines are available that protect against cervical 
cancers. Cervarix is one of the preventative vaccines (bivalent recombinant vaccine) 
that protect against two of high-risk HPV genotypes (HPV 16, 18) [Kearn & Harper, 
2008]. Gardasil is another HPV vaccine (quadrivalent recombinant vaccine) that 
protect against four HPV genotypes (HPV 6, 11, 16, 18) [Siddiqui & Perry, 2006]. 
HPV vaccine is produced by the expression of major and minor capsid protein and 
assembled into virus-like particles (VLPs) lacking viral DNA. The capsid proteins are 
immunogenic to induce the immune response. Other methods for prevention against 
HPV infection are using condom and spermicide. Recent studies have shown that 
condoms can reduce the risk of transmitting of HPV, but they are not 100% 
preventative, since HPV virus could be got by contact with scrotum, labia, or anus 
which are not covered by condom [Burd, 2003]. 
There are two preventative tools to decrease the cervical cancer in low and middle 
income countries (LMIC) since cancer is a main cause of death in LMIC. The 
combination of HPV vaccination and cervical screening are effective preventative 
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tools against developing cervical cancer and such tools are authorized by international 
organizations [Steben et al., 2012] . 
Epidemiology and incidence of BPV infection 
HPV is one of the most common causal agents for sexually transmitted (STD) disease 
among men and women worldwide. It is considered as most common viral STD in 
United State [Burd, 2003].The worldwide HPV prevalence among women with 
normal cytology is 11-12% with rate of24% in sub-Saharan Africa, 21% in Eastern 
Europe and 16% in Latin America. Whereas, among women with abnormal cytology, 
prevalence of HPV infection reported significantly higher (up to 98%) and it is 
proportional to the severity of the cervical lesions. HPV prevalence reaches 90% in 
women with grade 3 cervical intraepithelial neoplasia (CIN3) and invasive cancer 
(Forman et al., 2012).Worldwide, cervical cancer is the fourth most common cancer 
among women, with an estimated 83,195 new cases and 35,673 deaths in 2012 
[Ferlay et al., 2013]. More than 85% of these cases and deaths occur in developing 
countries [Jemal A et al., 2011]. HPV16 (3.2%) and HPV18 (1.4%) are the most 
prevalent HPV genotypes. 
In Guinea, the HPV prevalence is around 51% ( 4 7.9% among women with normal 
cervical cytology and 78.5% among women with abnormal cervical lesions). The 
prevalence of high-risk genotypes was 32.1% and the most common high-risk types 
with normal cervical cytology among Guinean women were HPV16 (6.7%), 45 
(4.7%), 52 (4.0%), and 18, 35 and 58 (3.2% each). On the other hand, the prevalence 
of low-risk genotypes with normal cervical cytology was 30.5% and the most 
common low-risk types were HPV66, 42 and 81. In the same study, they found that 
HPV16 was the most common high-risk genotypes (13.9%) among women with 
abnormal cytology [Keita et al., 2009]. 
On the other hand, in Europe, around 6.6% of women evaluate to develop 
cervical cancer each year and about 73.3 % of cervical cancer is due to HPV-16 
and/or HPV-18.In Italy, the HPV prevalence among Italian women was 8.8% in 
which HPV 16 was the most common high-risk type (32.6% of all HPV positive 
women). Based on the age group of the Italian study, HPV prevalence was (13.5%) at 
ages 25-39 years, (11.5%) at age 40-44 years, and approximately (5%) among older 
women [Ronco et al., 2005]. In France, HPV infection among French women with 
abnonnal cytology was significantly more prevalent (90%) than French women with 
10 
• 
• 
• 
normal cytology (48.3%). Furthermore, the most common HPV genotypes among 
French women were HPV-16 (14.8%), HPV-53 (9.0%), HPV-31 (8.7%), and HPV-51 
(7.5%), whereas HPV-18 (3.8%), HPV-6 (2.9%), and HPV-11 (0.4%) were less 
common [Casalegno et al., 2011]. The prevalence of HPV infection in the other 
European countries was (9.9%) Canada, (8.9%) England, (7.5%) Finland, (6.3%) 
Germany and (5.5%) Sweden [Casalegno et al., 2011]. 
In Arab world, cervical cancer is one of the most common type of cancer in Tunisia, 
but the rate differ depend on the region [KrennHrubec et al., 20ll].So the prevalence 
of HPV is relatively higher in prostitutes (39%) than in married women (14%). 
Furthermore, HPV genotyping analysis in Tunisian study showed that HPV 16 was 
the most common type among prostitutes while HPV 6 was the common among 
married women [Hassen et al., 2003].Furthermore, in Algeria, the prevalence ofHPV 
in the general Algerian population was 6.3%. HPV infection was significantly higher 
among women with polygamous marriages, divorced women and husband's 
extramarital sexual relationships. In the same study, authors showed that HPV 
infection among married women in Algeria is lower than in sub-Saharan Africa 
[Hammouda et al., 2011]. In Kuwait, the prevalence of HPV among women with 
normal cytology was 2.4% [Al-Awadhi et al., 2011], while prevalence ofHPV among 
women with abnormal cytology was 51% [Al-Awadhi et al., 2013]. 
The prevalence of HPV infections in women within the general population differs 
considerably between countries and regions, as well as within regions, ranging from 
1.6-41.9% [Vaccarella, Bruni, & Seoud, 2013].ln Extended Middle Eastern and North 
African (EMENA) countries, HPV prevalence reported between 0% and 25% in 
women with normal cytology and up to 98% in women with abnormal cytology 
[Khan, 2009; Seoud, 2012].Very limited data is available on the prevalence ofHPV 
infection in the Arab countries where social, cultural and sexual behaviors differ 
greatly from the more-well reported Western countries [Wellings et al., 2006]. 
Therefore, in the present study, for the first time identified the prevalence and 
genotypic distribution of HPV among general Arab women, with normal or abnonnal 
cytology, living in the state of Qatar . 
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Chapter 3-Materials and Methods 
Ethical consideration 
This study was approved by the Institutional Review Board of the Weill Cornell 
Medical College in Qatar (WCMCQ) and Research Office of Hamad Medical 
Corporations (HMC) Research Office, Doha, Qatar (Appendix I). 
Study Population: 
The study population of this study includes 3008cervical samples of Qatari women 
and women with Arab nationality living in Qatar were collected from Women's 
Hospital and Primary Health Care Corporation in Doha, Qatar between March 2012-
January 2013. 
Collection and cytological analysis of the samples: 
The cervical samples were collected in ThinPrep vials (BD SurePath ™) and were 
transported to the laboratory in an icebox container for further investigations. 
ThinPrep cytological smears were screened at Cytology lab, HMC and reported 
according to the Bethesda system for reporting of cervical cytology [Solomon D, 
Davey D 2002]. Furthermore, the age, nationality, clinical history, and cytological 
diagnosis of all the subjects were also retrieved and recorded. 
DNA Extraction: 
Viral DNA from cervical samples was extracted by QIAamp Min Elute virus spin kit 
according to manufacturer's instructions. Briefly, add 25 of protease in to 1.5 ml 
centrifuge tubes and then add 2001 of sample and 100lof AL buffer (contain 28g/ m1 
of carrier RNA). Furthermore, close the cap of tube and mix it by pulse vortexing for 
about 15 sec. Incubate at 65 for 15 min in heating block and centrifuge tube to remove 
the drops from the inside ofthe lid briefly. Then, add 250 I of ethanol to the sample, 
close the cap and mix it by pulse vortexing for 15 sec., incubate the lysate for 5 min at 
room temperature and then centrifuge it briefly. After that, applying all lysate onto 
QIAamp MinElute column carefully without wetting the rim of this column that 
contain filter to remove all the debris except the DNA of the virus. Centrifuge at 8000 
rpm for 1 min and place the QIAamp MinElute column in a clean 2 m1 collection 
tube, discard the collection tube containing the filtrate. Then, add 5001 of A WI buffer 
that prepare by adding 25 m1 of ethanol (95-1 00%) to 19 m1 of A WI buffer and store 
it at room temperature, centrifuge it at 8000 rpm for 1 min in clean 2 ml collection 
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tube, discard collection tube containing filtrate and add 500L of A W2 buffer that 
prepare by adding 30 ml of ethanol (95-100%) to a 13 ml AW2 buffer and store it at 
room temperature, centrifuge at 8000 rpm for 1 min in clean 2 ml collection tube, 
discard collection tube containing filtrate. After that, add 5001 of ethanol, centrifuge at 
8000 rpm for 1 min in clean 2 m1 collection tube, and discard collection tube 
containing filtrate. Place the column in a clean 2 m1 collection tube and then 
centrifuge at full speed 14000 rpm for 3 min to dry the column. Next, place the 
column into a new 2 m1 collection tubes, open the lid, and then incubate at 56°C for 3 
min to dry the membrane. Later, discard the collection tube with filtrate and place the 
column in a clean 1.5 m1 microcentrifuge tube and carefully open the lid and apply 
501 ofbuffer AVE or RNase-:free water to the center of the membrane, then close the 
lid and incubate at room temperature for 1 min. Finally, centrifuge tubes at full speed 
14000 rpm for 1 min. 
Measure the DNA concentration by using nanodrop: 
All the extracted DNA samples were subjected to nano-drop to measure the DNA 
concentration and 260/280 ratios were calculated. 
Detection of HPV infection by Real time PCR: 
To determine the presence of HPV-DNA, L1 consensus degenerated primer 
(GP5+/GP6+) (GP5+ 5'- TIT GTT ACT GTG GTA GAT ACT AC -3' and GP6+ 5'-
GAA AAA TAA ACT GTA AAT CAT ATT C -3') that amplify a conserved 150 bp 
sequence of the L1 open reading frame (ORF) and PC03/PC04 primers (Human ~-
globin as internal control) (PC03 5'- ACACAACTGTGTTCACTAGC-3' and PC04 
5' -CAACTTCATCCACGTTCACC-3 ') were used to ensure the DNA quality of the 
samples (Figure 1) [de Roda Husman et al., 1995]Real-time PCR amplification was 
carried out in ABI 7500 real-time PCR (Applied Biosystems). 
To detect the HPV DNA in clinical samples, we have carried out the real time PCR 
assay as follows: 2~ extracted genomic DNA (5ng/~) was combined with 12.5!-11 of 
2X SyberGreen (Applied Biosystems, Foster City, CA) containing ROX as a passive 
reference, 10pmol (10 J.JM) of each forward and reverse GP5+/6+ HPV and/or 
PC03/PC04 primers and the mixture was made up to 251Jl volume with nuclease free 
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water (Ambion, Austin, TX). The PCR amplification was initiated at 950C for 10 min 
and completed by 45 amplification cycles (denaturation at 950C for 20 sec, annealing 
at 500C for 30 sec and extension at 600C for 30 sec). 
All the samples were analyzed in duplicate on a 96 optical well reaction plate 
(Applied Biosystems). A positive control (plasmid HPV DNA gifted by Dr. Elham 
Hassen, Tunisia) and negative control (nuclease free water) were included in each 
amplification reaction. Real-time PCR amplification was carried out in ABI 7500 
real-time PCR (Applied Biosystems). 
E7t E1 I E2 lE51 I . L2 [ill 
I u 
'~. . 2000 3000 
.., .. >/'""' - \\~ 
·. 
·. 
My 11/09 ..._ _______ 450 bp 
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·. 
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Figure 1: HPV genome showing the targeted region (Ll gene) by HPV PCR specific 
primers (GP5+/6+) 
Data Analysis: 
Fluorescence spectra were recorded during the elongation phase of each PCR cycle. 
Sequence Detection Software (SDS vl. 7) of ABI 7500 real-time PCR was used to 
generate the amplification curve for each reaction. A DNA association curve was 
generated after each reaction to differentiate between specific amplicons from non-
specific products. SyberGreen fluorescence was measured during each step and the 
first derivative of the fluorescence was plotted as a function of the temperature. 
On the basis of the amplification curve, all samples with HPV amplification starting 
at and cycle and up to cycle number 40 (with a cut-off line of 0.2) were selected for 
the analysis (Figure 2a). HPV positive samples were detected by analyzing the 
amplicon dissociation curve and samples showing a melting Tm between 75 and 80°C 
were considered as positive (Figure 2b ). PCR products were also evaluated for 13 
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globin and Ll bands with 2% agarose gel stained with ethidium bromide and 
visualized with UV light (Figure 2c). 
' f ( 
trnear ampliflcatJon plot 
Cycles 
(a) (b) (o) 
Figure 2 (a): Amplification plot showing Cts, fluorescence detected 
(Rn) in each well (b) melting curve analysis (c) Gel electrophoretic 
analysis ofPCR products. Lane M: molecular marker; lanes 1,3,5,7,9 & 
11 clinical samples; -ve: negative control; +ve: positive control 
HPV Genotyping: 
HPV genotyping by RT-PCR kits and DNA seq11encing: The genotype-specific 
distribution of HPV in the samples, which tested positive for HPV DNA was 
determined by RT-PCR based kits (Sacace Biotechnology, Italy), which tests for 12 
high-risk HPV genotypes (1 6, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) and 2low-
risk HPV genotypes (6,11).Briefly, for detecting low risk HPV genotypes (6, 11) add 
10 !Jl of PCR mix-1 FRT, 5 !Jl of mix PCR buffer FRT containing TaqF DNA 
polymerase, and then add 10 !Jl of extracted DNA. For detecting high risk HPV 
genotypes (1 6, 18, 31, 33, 35, 39, 45, 51, 5~, 57, 58, and 59), add 3.5 1Jl ofPCR mix-
1, 4.5 !Jl of PCR buffer FRT containing hot start DNA polymerase and 5 !Jl of 
extracted DNA. The reactions were carried out according to the manufacturer's 
instructions (Sacace Biotechnology, Italy). 
All samples, which tested positive for HPV infection by RT-PCR, but where 
genotyping could not be assigne.d on the basis of the typing method described above, 
were subsequently subjected to sequencing (Genewiz [nc., NJ). PCR using 
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GP5+/GP6+ primer set and same reaction conditions as used during detection ofHPV 
infection in cervical samples was used to generate amplicons. In cases where the 
primary PCR yields were low, an additional round ofPCR using 2 ul of the primary 
PCR product and the same primers was done to ensure enough yields to perform 
direct sequencing. The PCR products were purified using MinElute PCR Purification 
Kit according to manufacturer's instructions (Qiagen, Valencia, CA). Purified 
products were sequenced using the Sanger method (Genewiz, South Plainfield, NJ) 
with GP6+ primer. The sequences were aligned using SeqMan Pro module of Laser 
gene 10.0 software (DNASTAR, Madison, WI). For genotyping, 35 bp sequences 
adjacent to the GP5+ primer-binding site was used for nucleotide-nucleotide BLAST 
analysis (blastn) against known HPV genotype sequences stored in the GenBank 
database (www.ncbi.nlm.nih.gov/ BLAST/). This 35 bp hyper-variable region of the 
Ll gene has been shown to be sufficient for distinguishing between various HPV 
genotypes [Feoli-Fonseca et al., 1998]. Genotypes were assigned only when there was 
a 100% similarity between the 35bp query and the subject sequence. 
Statistical analysis 
Sample characteristics including age, cytology results, clinical findings and 
nationality were summarized using frequency distnbutions to generate the numbers 
and percentages (Table 1). The prevalence ofHPV positivity by each ofthe above-
mentioned characteristics was assessed using the chi-squared test (Table 1). 
Unadjusted and adjusted odds ratios (ORs) for HPV positivity along with their 95% 
confidence intervals (CI) calculated according to the selected characteristics 
summarized in Table 1, using bivariate and multivariable logistic regressions 
respectively. The prevalence ofHPV along with the 95% CI between Qatari and non-
Qatari was plotted against age groups (Figure 1 ). Chi-squared test for trend was used 
to assess whether there is an increasing or decreasing trend in the proportions of HPV 
positivity by age, between Qatari and non-Qatari. The distribution of HPV genotypes 
was sununarized using frequency distribution and stratified by cytology results 
(abnormal versus normal cytology) (Table 2). Statistical analysis was performed using 
IBM SPSS version 21.0. A p-value ofless than 0.05 was considered significant. 
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Chapter 4- Results 
Demographic, clinical and cytological characteristic of the study population 
In this study, a total of 3008 cervical samples were collected from Qatari and non-
Qatari Arab women visiting Women's Hospital, HMC and Primary Health Care 
Corporation, Doha, Qatar. These women came for either routine gynecological care 
and for different clinical conditions such as vaginal discharge, vaginal bleeding, 
genital warts, post-coital bleeding, cervical erosion, vulva itching, lower abdominal & 
pelvic pain, primary & secondary infertility and menorrhagia. The age range was 16-
84 years with a mean age of 41.6 years (SD=10.9). The distribution of patients based 
on their age groups 16-24, 25-34, 35-44, 45-54, and ~55 was 136 (4.5%), 756 
(25.1%), 919 (30.6%), 835 (27.8%), and 362 (12%) respectively (Table 1). Total 
46.7% of the women in the sample population were Qataris with the rest belonging to 
other Middle Eastern, North and East African countries in the League of Arab States 
(Table 1), which is reflective ofthe make-up of the general Arab society in Qatar. 
Table 1 show clinical findings and majority of women underwent routine 
gynecological care (79.8%) and only 20.2% were symptomatic. Furthermore, based 
on cytological diagnosis, 98.4 % of the women (n=2959) had normal cytology 
without any lesions. A minority of women (n=49, 1.6%) had abnormal cytology with 
either low-grade squamous intraepithelial lesion (LGSIL) and/or high-grade 
squamous intraepitheliallesion (HGSIL). 
HPV prevalence in study population (Qatari and Arab national) women 
The overall HPV prevalence in Arab women was 6.0% (6.2% in Qatari and 5.9% non-
Qatari) (Table 1). Of the non-Qatari Arab women, HPV prevalence was as follows: 
5.6% in Egyptian, 4.5% in Arabian Peninsula, 6.5% in Fertile Crescent, 7.4% in 
North Africa and 6.5% in East Africa (Table 1). Furthermore, 5.8% HPV prevalence 
was found among women with normal cytology and 18.4% among women with 
abnonnal cytology. Based on cytological findings, 36 samples were low-grade 
squamous intraepithelial lesions of which, 8 were HPV positive and 13 high-grade 
squamous intraepitheliallesions ofwhich, 1 was positive for HPV. The odds ofHPV 
positivity among participants with abnormal cytology were almost four times the odds 
ofHPV positivity among participants with normal cytology (OR: 3.68, 95%CI: 1.75; 
7.75) (Table 1). 
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The prevalence of HPV infection based on age groups among Qatari and non-
Qatari Arab women 
HPV prevalence overall was found higher in the age group >55 (Table 1 ). HPV 
prevalence increased with age in non-Qatari women, while no such trend was seen in 
Qatari women (Figure !).Furthermore, among Qatari women, HPV prevalence was 
higher (7.1 %) in 25-34 age group and 8.5% in >55 age group of non-Qatari women 
(Figure 1 ). However, by chi-square analyses, no significant difference was found in 
HPV prevalence 1Jetween the Qatari and non-Qatari Arab nationals across the 
different continuous age groups used in this study. 
Distribution of HPV genotypes in Arab women 
The distribution of HPV genotypes among the 182 HPV positive DNA samples of 
Arab women with normal and abnormal cytology was evaluated and examined based 
on the number of HPV genotypes in a single sample. Results in table 2 show that 
women were divided into two groups based on their cytological diagnosis into women 
with normal cytology (N= 2959) and women with abnormal cytology (N= 49). 
Among HPV positive women with normal cytology, 144 (83.2%) diagnosed with 
single HPV genotype, 19 (10.9%) with two HPV genotypes, 5 (2.9%) with multiple 
HPV genotypes and 5 (2.9%) remained uncharacterized and have been listed in Table 
2 as unknown. On the other hand, among HPV positive women with abnormal 
cytology 5 (55.6%) had single HPV genotype, 3 (33.3%) two HPV genotypes and 
1(11.1 %) had multiple HPV genotypes. 
HPV 81 was the most frequent low-risk genotype among women with both 
normal (74.0%) and abnormal (33.3%) cytology. Women with HPV 81 genotype was 
significantly less (86.0%) at risk of showing abnormal cytology than women with 
high-risk genotypes (OR: 0.14, 95%CI: 0.03-0.58), which further enforces the low 
risk classification of this HPV genotype, as described in Table 3.The only 
intermediate risk HPV genotype identified was HPV 67, which had 3.5% prevalence 
in women with normal cytology. While, HPV16 (4.6%) was identified as the 
predominant high-risk HPV genotype, followed by HPV 59 (3.5%) and 56 (2.9%) in 
women with normal cytology whereas among women with abnonnal cytology, the 
most common identified HR genotypes were HPV 16, 18 and 56 (22.2% each) (Table 
2). 
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Table 1: Unadjusted and adjusted odd ratios (ORs) for HPV positivity and their 
corresponding 95% confidence intervals (Cis) according to age groups, cytology 
results, clinical findings and nationality among 3008 women in Qatar 
Total No. Women HPV positive, Unadjusted OR 
N(%) (95% CI) 
Age groups 
16-24 136 (4.5) 7 (5.1) 1 
25-34 756 (25.1) 44 (5.8) 1.14 (0.50-2.58) 
35-44 919 (30.6) 51 (5.5) 1.08 (0.48-2.44) 
45-54 835 (27.8) 54 (6.5) 1.27 (0.57-2.86) 
~55 362 (12.0) 26 (7.2) 1.43 (0.60-3.37) 
Cytology Results 
Normal Cytology 2959 (98.4) 173 (5.8) 1 
Abnormal Cytology 49 (1.6) 9 (18.4) 3.62 (1.73-7.59)* 
Clinical Findings 
Routine smear test 2401 (79.8) 142 (5.9) 1 
Symptomatic 607 (20.2) 40 (6.6) 1.12 (0.78-1.61) 
results££ 
Nationality 
Qatari 1404 (46.7) 87 (6.2) 1 
Non Qatari 1604 (53.3) 95 (5.9) 0.95 (0.71-1.29) 
Nationality 
Qatari 1404 (46.7) 87 (6.2) 1 
Egyptian 465 (15.5) 26 (5.6) 0.90 (0.57-1.41) 
Arabian peninsulaS 310 (10.3) 14 (4.5) 0.72 (0.40-1.28) 
Fertile crescent£ 566 (18.8) 37 (6.5) 1.06 (0.71-1.58) 
North Africa# 95 (3.2) 7 (7.4) 1.20 (0.54-2.68) 
East Africa" 168 (5.6) 1.1 (6.5) 1.06 (0.55-2.03) 
*p-value<0.05 
s Arabian Peninsula (KSA, Kuwait, Bahrain, UAE, Oman, Yemen) 
£Fertile Crescent (Syria, Lebanon, Jordan, Palestine, Iraq, excluding Egypt) 
#North Africa (Morocco, Algeria, Tunisia, Libya, Mauritania) 
"East Africa (Somalia, Djibouti, Sudan, Comoros) 
Adjusted OR 
(95% CI) 
1 
1.20 (0.53-2.73) 
1.15 (0.51-2.59) 
1.36 (0.60-3.07) 
1.49 (0.63-3.54) 
1 
3.68 (1.75-7.75) 
1 
1.15 (0.80-1.65) 
1 
1.00 (0.73-1.36) 
££ Symptomatic results include: cervical erosion, genital warts, lower abdominal pain, 
menorrhagia, pelvic pain, post coital bleeding, primary infertility, secondary infertility, 
vaginal bleeding, vaginal discharge, vaginal spotting and vulva itching 
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Figure 3: Prevalence of HPV by age groups and nationality and their 
corresponding 95% confidence interval (CI) among Qatari and non-Qatari Arab 
women 
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Table 2: The distribution of HPV types in 3008 Arab women in Qatar 
General Arab Po[!ulation in Qatar 
Normal Cytologx {N=2959} Abnormal C11olon- (49} 
Single Double Multiele Unknown Total Percent Single Double Multil!le Unknown Total 
144 19 5 5 173 5.8 5 3 I 0 9 
4 2 2 8 4.62 0 1 I 2 
0 0 3 3 1.73 0 2 0 2 
I 2 l 4 2.31 0 1 0 1 
I 2 I 4 2.31 0 0 0 0 
0 1 1 2 1.16 0 0 0 0 
0 I I 2 1.16 0 0 0 0 
2 3 0 5 2.89 0 0 0 0 
0 I 1 2 1.16 0 0 I I 
l 0 0 l 0.58 0 0 0 0 
0 4 1 5 2.89 I I 0 2 
1 0 1 2 1.16 1 0 0 [ 
4 ! I 6 3.47 () 0 0 0 
4 6 3.47 0 0 0 0 
I 3 0 4 2.31 0 0 0 0 
4 5 2 II 6.36 0 I 1 2 
119 9 0 128 73.99 3 0 0 3 
2 3 0 5 2.89 0 0 0 0 
Table 3: The distribution and prevalence of HPV types among women with 
normal and abnormal cytology 
High Risk 
httermediare Risk 6 0 6 
kow Risk 148 5 153 
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All{N=3008} 
Percent Total Percen1 
18.4 182 6.1 
22.2 10 5.49 
22.2 5 2.75 
11.1 5 2.75 
0.00 4 2.20 
0.00 2 l.lO 
0.00 2 1.10 
0.00 5 2.75 
Il.l 3 1.65 
0.00 I 0.55 
22.2 7 3.85 
22.2 3 1.65 
0.00 6 3.30 
0.00 6 3.30 
0.00 4 2.20 
22.2 13 7.14 
33.3 131 72.0 
0.00 5 2.75 
3.3o/o 
84.t9/o 
• 
• 
• 
Chapter 5- Discussion 
HPV is one of most conunonly occurring sexually transmitted disease. There are 
limited studies available on the prevalence ofHPV infection and the distribution of 
different HPV genotypes in Arab countries. This may be due to the presence of a 
closed society, conservative socio-sexual norms in the Middle Eastern countries and 
sexual transmission nature of the disease; it has often been ignored in this region. This 
is the first study describing the prevalence of HPV infection and distribution of HPV 
genotypes in a large cohort of Arab women with normal and abnormal cytology in the 
State of Qatar. Currently, more than 200 HPV genotypes have been identified and 
based on their oncogenic potential via associations with cervical cancer and 
precancerous lesions, about 30 to 40 genotypes, cause genital tract infection in 
human, are divided into high-risk (HR), causing cervical neoplasia and low-risk (LR) 
HPV genotypes, which causes benign signs and symptoms[ Clifford, Smith, Plununer, 
Munoz, & Franceschi, 2003]. 
In this study, the prevalence of HPV infection among Arab women with 
normal and abnormal cytology is very low (5.8% and 18.4% respectively) compared 
with previous reports from EMENA countries except Kuwait and Pakistan where the 
HPV prevalence among women with normal cytology was lower (2.4% and 2.2% 
respectively) [Al-Awadhi et al., 2011; Franceschi et al., 2010] than our results in 
Qatar. Whereas, HPV prevalence among women with abnormal cytology was higher 
in Kuwait and Pakistan (51% and 27.3% respectively) [Al-Awadhi et al., 
2013;Franceschi et al., 2010]than our study (18.4%). The reason for these differences 
in prevalence rates could be partly due to the differences in the methodologies which 
were used to detect HPV infection especially since no significant differences in the 
HPV prevalence among Qatari and non-Qatari Arab women living in Qatar was 
identified in this study. The HPV prevalence of 18.4% in women with cervical 
abnormalities in our study is to be expected since virtually all studies from all over the 
world have reported the same finding [Munoz et al., 2000] . 
The Age-specific distribution of HPV prevalence in this study shows a bell shaped 
curve in Qatari women, with a peak between 25 and 34 years of age, and dropping 
down at > 55 years of age, whereas HPV prevalence increased with age in non-Qatari 
women with highest HPV infection prevalence in age C!: 55 (8.5%). The peak at early 
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age (25-34 years) in Qatari women was similar to the findings in Latin America, Italy, 
Netherlands, Spain, Argentina, Korea and Canada who also show increased HPV 
prevalence at early age (<25 years) [Franceschi et al., 2006; Bruni et al., 2010]. The 
highest peak at older menopausal age (;=: 55) of HPV prevalence in non- Qatari 
women is similar to studies done in North America, Africa, Chile, Colombia and 
Mexico [Franceschi et al., 2006], where increased HPV prevalence was found high in 
postmenopausal age groups [Bosch, Qiao, & Castelleague, 2006]. On the other hand, 
China, India and in Nigeria, the prevalence ofHPV infection was reported high in all 
the age groups. Although, the reason for the higher prevalence of HPV in >55 years 
age group in non-Qatari were not clear, but this could be due to poor or the lack of 
effective cervical cancer screening method and lack of using the most sensitive HPV 
detection methods such as molecular tools [Richter, Becker, Horton, & Dreyer, 2013]. 
The detection of newly HPV infection in older women could be more likely due to 
reactivation of latent HPV compared to younger women [Velicer, Zhu, Vuocolo, Liaw 
, & Saah, 2009]. 
In our study we found a heterogeneous distribution of HPV genotypes, possibly due 
to broad geographical and cultural range of the nationalities included in this cohort. 
In the present study, HPV 16 was the most common genotype followed by HPV 
56,59, 45,31, 33, 18, 35, 39, 58, 51, and 52 among the high risk HPV group and HPV 
67 in intermediate risk group. This is in agreement with global studies where HPV 16 
was identified as the most common HPV genotype [Clifford, Smith, Aguado, & 
Aguadoi, 2003], except in western Africa, where HPV 31 was the most prevalent 
[Bruni et al., 2010]. Similarly, in women with normal cytology, HPV 6, 11, 16 and 
18 were the most commonly seen HPV genotypes in extended Middle East and North 
Africa region [Oakeshott et al., 2012]. In addition, several studies show that HPV 16, 
18, 45, 31, 33, 52, 58, and35 are accountable for 95% of cervical cancers 
[Walboomers et al., 1999; Khan et al., 2009]. In our study, high-risk HPV genotypes 
were found in both women with normal and abnonnal cytology. HPV16 was the most 
cotmnon high-risk genotype (4.6%), followed by HPV 59 (3.5%), 45 (2.9%) and 56 
(2.9%) in normal cytology, whereas, prevalence of HPV 16, 18 and 56 was high 
among abnormal cytology (22.2% each). 
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Moreover, the HPV genotype distribution varies based on the geographical 
variations and that could be based on samples size and geographical distribution 
[Haghshenas et al., 2013]. Study done in South Africa showed that HPV 52 was the 
predominant type (12.2%) in ASCUS women, followed by HPV 45 (6.1%), while in 
LGSIL women, HPV 52 was the most common type (17.5%), followed by HPV 53 
(15.8%) and HPV 16 and HPV 35 (both 12.3%). In HGSIL women, HPV 16 and HPV 35 
were the most predominant types (both 18.9%) and HPV 18 was found at (7.6%) of 
women [Allan, Marais, Hoffman, Shapiro, & Williamson, 2008]. 
When taken into consideration the fact that HPV 16 and 18, taken together are 
responsible for 70% of the cervical cancer cases [Walboomers et al., 1999] 
worldwide, these results clearly highlight the need for HPV screening for cervical 
cancer even in the absence of cytological abnormalities and demonstrate the 
inadequacy of cytology based assays for cancer screening. 
When a comparison was made of women with cytological findings and HPV 
genotype distribution, in this study, HPV 81 was the most frequent low-risk genotype 
among women with both normal (74%) and abnormal (33.3%) cytology. The 
unexpectedly much higher HPV genotype 81 prevalence than HPV 16 in our study 
was also seen in a previous study done on Southern Chinese women [Ngami Na 
Chloe Co et al., 2013] and can be attributed to variations in the biological distribution 
of HPV genotypes and the sensitivities of different methods used for HPV detection 
[Ngami Na Chloe Co et al., 2013]. HPV 81 is classified as a low risk genotype and 
has not been reported in high numbers in worldwide population studies however it is 
one of the most frequently observed HPV genotypes in HIV-positive patients and is 
also reported to be associated with precancerous or cancerous lesions [Tomesello et 
al., 2008; Choi et al., 2009; Garbuglia AR, et al., 2012; Ngai Na Chloe Co et al., 
2013; Al-Awadhi R et al., 2013]. Cerqueira et al. (2007) has reported a high 
prevalence of HPV 81 (14%) in HIV-positive Brazilian women [Cerqueira et al., 
2007]. In our study, we also found an intratypic variant ofHPV 81, which matched an 
unique isolate identified in an HIV-1 positive patient in India [Mullick et al., 2011 
(Accession: JQ353697)]. Although, our study indicate a higher association of HPV 
genotype 81 with women with normal cytology as opposed to abnormal cytology 
indicating a low oncogenic potential of this genotype. However given its occurrence 
in multiple infections and precancerous lesions, it is a possibility that infection with 
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HPV genotype 81 may make the environment more conducive for co-infection/prime 
the environment for cancerous conversion in case of infection with other high risk 
HPV genotypes. 
Infections with numerous HPV types are generally found in women who are 
sexually active, especially in HIV-infected women [Marais et al., 2008; Plummer et 
al., 2011],but less frequently in cervical carcinoma than in normal cytology [An HJ et 
al., 2003]. However, other studies have found multiple HPV infection to be associated 
with a significantly increased risk of high-grade squamous intraepithelial lesion 
compar~d to infection with a single HPV type [Spinillo et al., 2009]. In the present 
study, mostly women with normal cytology had a single HPV type infection (81.8%) 
but infection with double and multiple HPV types has also been observed frequently 
(15.38%) in patients with cytological abnormalities, which is similar with previous 
reports [Ho GY et al., 1998; Herrero R et al., 2000]. Furthermore, we found HPV 
genotype 81 (61.7%), 11 (6.1%), 16 (4.7%),56 (3.3%) and 59 (2.8%) were most 
prevalent as single infections in all age groups. However, in an infection with more 
than one genotype, the most common HPV types were HPV16/18 and 11/81 (13.6%) 
and HPVll/16/18 and 16/18/59 (16.6%). 
In conclusion, our study showed a relatively low prevalence (6%) of HPV 
infection and presence of a varied genotypic profile ofHPV with a high prevalence of 
low risk HPV genotype 81 among the Arab women residing in State of Qatar when 
compared to the Middle Eastern and North African (MENA) countries. When 
considering a prophylactic vaccine, the data from this study show that the 
quadrivalent vaccine has the potential to prevent HPV infections in Arab women. 
However, as remarkable differences were noted in our study population with a high 
prevalence ofHPV 81 and other types such as HPV 16, 56, 59 and 67, the potential 
for cancer prevention in this region would rise if these frequent high and intermediate 
risk HPV genotypes and possibly HPV 81 are also included in future HPV vaccines 
targeting this specific population. 
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Chapter 6- Conclusion 
Human papillomavirus (HPV) are the most commonly known sexually transmitted 
agents. To date, few reports are available on distribution of most prevalent and 
variants types of HPV in Arab women. Therefore, the aim of this study was to 
determine the age specific distribution of HPV types among Arab women being 
subjected to routine Pap smear test in State of Qatar. Based on the collected data in 
this study, out of3008 collected Pap smear samples, HPV DNA was detected in 182 
women (6%), and 17 different HPV genotypes were detected, comprising high-risk, 
intermediate and low-risk genotypes. The prevalence of HPV infection was seen in 
6.2% Qatari and 5.9% non-Qatari women. With regard to age, 5.1% HPV infection 
were found in women 16-24 years of age, 5.8% in women 25-34 years of age, 5.5% in 
women 35-44 years of age, 6.5% in women 45-54 years and 7.2% in women more 
than 55 years old. 
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